Cyclosporine - cyclosporine microemulsion
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Maintenance Liver Transplant Patients With New Onset Diabetes
Conditions
Maintenance Liver Transplant Patients With New Onset Diabetes
Trial Timeline
Feb 1, 2004 → Dec 1, 2005
NCT ID
NCT00171717About Cyclosporine - cyclosporine microemulsion
Cyclosporine - cyclosporine microemulsion is a approved stage product being developed by Novartis for Maintenance Liver Transplant Patients With New Onset Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT00171717. Target conditions include Maintenance Liver Transplant Patients With New Onset Diabetes.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00171717 | Approved | Completed |
Competing Products
20 competing products in Maintenance Liver Transplant Patients With New Onset Diabetes
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2422347 + placebo | Eli Lilly | Phase 2 | 52 |
| LY2624803 - Solution + LY2624803 - Capsule + Placebo - Solution + Placebo - Capsule | Eli Lilly | Phase 1 | 33 |
| Zolpidem MR + Estazolam | Astellas Pharma | Approved | 85 |
| zolpidem MR + nitrazepam + placebo | Astellas Pharma | Phase 3 | 77 |
| FK199B + Zolpidem | Astellas Pharma | Phase 3 | 77 |
| ASP7991 | Astellas Pharma | Phase 1 | 33 |
| Graceptor® | Astellas Pharma | Pre-clinical | 23 |
| Zolpidem MR + Zolpidem IR | Astellas Pharma | Approved | 85 |
| Zolpidem MR + Zolpidem | Astellas Pharma | Phase 3 | 77 |
| Lemborexant | Eisai | Phase 2 | 52 |
| Lemborexant + Placebo | Eisai | Phase 3 | 77 |
| Lemborexant | Eisai | Pre-clinical | 23 |
| Eszopiclone + Fluoxetine + Placebo | Sumitomo Pharma | Approved | 85 |
| Org 50081 + Org 50081 + Placebo + zopiclone | Merck | Phase 1 | 33 |
| esmirtazapine | Merck | Phase 3 | 77 |
| Esmirtazapine | Merck | Phase 3 | 77 |
| Suvorexant + Placebo | Merck | Phase 3 | 77 |
| Esmirtazapine + Placebo | Merck | Phase 3 | 77 |
| Enteric-coated Mycophenolate sodium (EC-MPS) + Mycophenolate mofetil | Novartis | Approved | 85 |
| Enteric-coated Mycophenolate sodium (EC-MPS) | Novartis | Approved | 85 |